查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011854

幹細胞療法市場：2026-2032年全球市場預測（依治療方法、細胞來源、技術、給藥途徑、應用、治療領域及最終用戶分類）

Stem Cell Therapy Market by Therapy Type, Cell Source, Technology, Mode of Administration, Application, Therapeutic Areas, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，幹細胞治療市場價值將達到 50.8 億美元，到 2026 年將成長至 57.9 億美元，到 2032 年將達到 133.5 億美元，複合年成長率為 14.79%。

主要市場統計數據
基準年 2025 50.8億美元
預計年份：2026年 57.9億美元
預測年份 2032 133.5億美元
複合年成長率 (%) 14.79%

我們正在透過創新的幹細胞療法開啟醫療保健的新時代，徹底改變患者的治療效果，並重新定義全球治療模式。

幹細胞療法正迅速崛起為現代醫學中最具前景的新興領域之一，為修復受損組織、調節免疫反應以及改善多種急慢性疾病的患者預後提供了前所未有的潛力。透過利用這些多功能和多功能細胞固有的再生能力，研究人員和臨床醫生正在重新定義治療模式，涵蓋從神經退化性疾病到心血管疾病等許多領域。細胞培養技術、基因編輯、生物材料和法規結構方面的進步，推動了幹細胞療法從實驗室研究走向實際臨床應用。

突破性發現和技術進步如何從根本上改變幹細胞療法的發展和廣泛應用？

近年來，幹細胞治療領域經歷了變革性的轉變，這主要得益於基因編輯、誘導性多功能幹細胞中的基因缺陷成為可能，從而為罕見遺傳疾病的個人化再生醫學鋪平了道路。

分析近期美國關稅政策對幹細胞療法供應鏈和研究前景的廣泛外溢效應。

美國於2025年初實施的新關稅對整個幹細胞治療供應鏈和研究生態系統產生了一系列連鎖反應。關鍵原料、特殊試劑和高精度設備（其中許多來自海外）成本的上漲，對學術研究機構和商業生產商都造成了影響。因此，採購團隊正在重新談判長期契約，並尋找具備本地生產能力的替代供應商。

透過檢驗不同的治療方法、細胞來源、技術、給藥途徑、應用領域、治療標靶和最終用戶，可以獲得關鍵見解。

要深入了解幹細胞治療市場，必須綜合考慮治療類型、細胞來源、技術、給藥途徑、應用領域、治療重點和終端使用者群體之間的相互作用。異體療法利用供體來源的細胞，由於其生產效率的規模經濟優勢，正蓬勃發展；而自體療法儘管個體化治療成本較高，但因其個性化的安全性，仍然備受青睞。在細胞來源方面，由於造血幹細胞和間質幹細胞平台的成熟，成體幹細胞仍是主流。另一方面，神經前驅細胞因其在中樞神經系統疾病治療中的應用而日益受到關注。胚胎幹細胞在需要多功能的領域中佔據了一席之地，而羊水和臍帶血等周產期來源的細胞則兼具倫理可接受性和強大的分化潛能。

分析美洲、歐洲、中東和非洲以及亞太地區幹細胞治療市場的主要區域趨勢、成長機會和新興發展。

區域趨勢在幹細胞療法研發和商業化過程中發揮著至關重要的作用。在美洲，美國憑藉其穩健的資金籌措環境、完善的臨床試驗基礎設施以及兼顧病患安全和快速核准流程的法規結構，佔據主導地位。加拿大正透過對轉化研究中心進行策略性資助來鞏固其地位，而拉丁美洲國家則開始利用其成本效益高的臨床夥伴關係和政府扶持政策來吸引國際獎勵。

對世界領先的幹細胞治療研發公司在不斷發展的產業格局中的策略定位和創新藍圖檢驗。

幹細胞療法的競爭格局是由那些在科學創新、監管合規和策略夥伴關係表現卓越的機構所塑造。主要企業正透過將專有技術與強大的生產平台結合，展現其將早期研究推進至臨床實驗的能力。一些創新者專注於基因編輯的異體細胞株，以應對罕見遺傳疾病；而另一些創新者則致力於最佳化間質幹細胞構建體，用於治療發炎性疾病和組織修復。

旨在加速幹細胞治療領域的創新、最佳化營運系統和加強合作的實用策略和最佳實踐。

產業領導企業應優先投資模組化生產系統，以實現快速規模生產並靈活適應多種細胞類型和治療標靶。透過採用一次性生物反應器和封閉式系統處理，企業可以最大限度地降低交叉污染風險，並加速不同設施間的技術轉移。同時，與試劑供應商和專用設備供應商建立策略合作夥伴關係，可確保優先獲得關鍵投入，並促進合作舉措。

透過結合質性訪談、量化資料分析和專家檢驗的嚴謹調查方法，我們確保了對幹細胞療法的紮實了解。

本研究採用融合定性和定量資料的混合方法，對幹細胞治療領域進行了全面概述。初步調查透過對領先生物製藥公司高階主管、監管代表、學術研究人員和契約製造專家進行深度訪談完成。這些訪談使我們深入了解了研發挑戰、投資重點和推廣應用障礙，包括一些細微差別。

整合關鍵見解並確定未來路徑，以推動全球幹細胞應用領域下一代治療突破。

對技術進步、政策轉變和市場動態的全面分析表明，幹細胞療法正處於發展的關鍵成熟階段。基因控制和細胞製造技術的突破正在克服先前阻礙規模化和一致性的瓶頸。同時，不斷完善的法規和政策正在降低研發過程中的風險，並創造有利於創新的環境。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 幹細胞治療市場依治療方法分類

  • 順勢療法
  • 自體療法

第9章 幹細胞療法市場（依細胞來源分類）

  • 成體幹細胞
    • 造血幹細胞
    • 間質幹細胞
    • 神經幹細胞
  • 胚胎幹細胞
  • 誘導性多功能幹細胞
  • 周產期幹細胞
    • 羊水來源幹細胞
    • 臍帶幹細胞

第10章 幹細胞療法市場：依技術分類

  • 生物材料療法
  • 體外培養
  • 基因編輯技術
  • 利用支架進行治療

第11章 依給藥途徑分類的幹細胞治療市場

  • 關節內
  • 肌肉內部
  • 靜脈

第12章 幹細胞治療市場：依應用領域分類

  • 藥物發現與開發
  • 再生醫學
  • 組織工程

第13章 幹細胞治療市場（依治療領域分類）

  • 心血管疾病
  • 血液學
  • 肌肉骨骼疾病
  • 神經系統疾病
  • 腫瘤學

第14章 幹細胞治療市場：依最終使用者分類

  • 學術和研究機構
  • 生物製藥公司
  • 醫院和診所
  • 幹細胞庫

第15章 幹細胞治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 幹細胞治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 幹細胞治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 美國幹細胞治療市場

第19章 中國幹細胞治療市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Beike Biotechnology Co., Ltd.
  • BrainStorm Cell Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • CellProthera SAS
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Garuda Therapeutics
  • Holostem Terapie Avanzate Srl
  • Jasper Therapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Juvena Therapeutics Inc.
  • Kangstem Biotech Co., Ltd.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Lonza Group AG
  • Medeze Group
  • Merck KGaA
  • Mesoblast Ltd.
  • Novo Nordisk A/S
  • Plasticell
  • ReNeuron Group PLC
  • SQZ Biotechnologies Company by Stemcell Technologies
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • US Stem Cell Inc
  • Umoja Biopharma
  • Vericel Corporation
Product Code: MRR-431752EA49AD

The Stem Cell Therapy Market was valued at USD 5.08 billion in 2025 and is projected to grow to USD 5.79 billion in 2026, with a CAGR of 14.79%, reaching USD 13.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.08 billion
Estimated Year [2026] USD 5.79 billion
Forecast Year [2032] USD 13.35 billion
CAGR (%) 14.79%

Pioneering a New Era in Healthcare with Innovative Stem Cell Therapies Revolutionizing Patient Outcomes and Redefining Treatment Paradigms Globally

Stem cell therapy is rapidly emerging as one of the most promising frontiers in modern medicine, offering unprecedented potential to repair damaged tissues, modulate immune responses, and transform patient outcomes across a variety of chronic and acute conditions. By harnessing the innate regenerative capabilities of these pluripotent and multipotent cells, researchers and clinicians are redefining treatment paradigms from neurodegenerative disorders to cardiovascular disease. The convergence of advances in cell culture techniques, gene editing, biomaterials, and regulatory frameworks has elevated stem cell interventions from laboratory curiosities to viable clinical applications.

Against this backdrop, the executive summary provides a concise yet thorough exploration of the forces reshaping the stem cell therapy landscape. It examines groundbreaking technological developments, analyzes the implications of recent policy shifts, and distills critical insights drawn from segmentation and regional dynamics. Emphasis is placed on understanding how emerging cell sources and manufacturing platforms are unlocking new therapeutic avenues, while a spotlight on key stakeholders reveals strategic pathways to leadership.

Drawing on primary interviews with industry experts, secondary literature, and rigorous data validation, this overview equips decision-makers with the knowledge required to navigate complexities and capitalize on opportunities. Whether you are a researcher seeking collaboration, an investor assessing risk, or a corporate strategist charting growth, this executive summary lays the foundation for informed action and sustained innovation.

How Groundbreaking Discoveries and Technological Convergence Are Driving Fundamental Shifts in Stem Cell Therapy Development and Adoption

Recent years have witnessed transformative shifts in the stem cell therapy landscape, driven by breakthroughs in gene editing, induced pluripotent stem cell (iPSC) reprogramming, and automated manufacturing platforms. These innovations are converging to accelerate clinical translation and broaden therapeutic reach. For instance, the refinement of CRISPR-based editing techniques has enabled precise correction of genetic defects in patient-derived cells, opening doors to personalized regenerative interventions for rare inherited disorders.

Parallel advances in scaffold-based delivery systems and biomaterial engineering are enhancing cell viability and targeted engraftment, mitigating historic challenges associated with retention and survival at injury sites. Ex vivo expansion technologies further bolster scalability by allowing the production of high-quality cell populations under controlled conditions, thereby reducing variability and ensuring consistency across batches.

Moreover, public-private partnerships and cross-sector collaborations have fostered shared infrastructure, regulatory guidance, and pooled expertise. These cooperative frameworks are streamlining early-phase clinical trials, facilitating accelerated approval pathways, and de-risking investments. By strategically aligning research institutions, biopharmaceutical firms, and clinical networks, the industry is primed to transition innovative concepts into widespread adoption, marking a pivotal shift from proof-of-concept studies to robust, scalable therapeutic programs.

Analyzing the Broad Ripple Effects of Recent United States Tariff Policies on the Stem Cell Therapy Supply Chain and Research Outlook

The introduction of new tariffs by the United States in early 2025 has triggered a series of reverberations throughout the stem cell therapy supply chain and research ecosystem. Key raw materials, specialized reagents, and high-precision instrumentation-many of which are sourced internationally-have seen input costs rise, affecting both academic laboratories and commercial manufacturers. As a result, procurement teams are renegotiating long-term contracts and exploring alternative suppliers with regional manufacturing capabilities.

In addition to elevated costs, extended customs clearance times have disrupted just-in-time inventory models, compelling facilities to build buffer stocks and adapt warehouse management systems. This shift has inadvertently underscored the value of strategic localization, with some organizations electing to repatriate critical processes closer to end-markets to mitigate tariff exposure.

On the research front, regulatory bodies have shown a willingness to accommodate conditional approvals and rolling submissions in response to supply chain pressures. This flexibility has enabled certain clinical programs to maintain momentum, even as budgetary allocations are rebalanced to absorb incremental import duties. Looking ahead, stakeholders are reevaluating risk management frameworks, prioritizing vertical integration, and forging cross-border alliances to preserve operational continuity and capitalize on evolving policy landscapes.

Unlocking Critical Insights by Examining Diverse Therapy Types, Cell Sources, Technologies, Administration Modes, Applications, Therapeutic Targets, and End Users

Insight into the stem cell therapy market emerges most clearly when one considers the interplay of therapy types, cell sources, technologies, administration routes, application areas, therapeutic focus, and end-user segments. Allogeneic therapies, which leverage donor-derived cells, are gaining momentum thanks to scalable manufacturing efficiencies, whereas autologous approaches continue to appeal for their personalized safety profile despite higher individualized processing costs. From a sourcing perspective, adult stem cells remain a mainstay thanks to established hematopoietic and mesenchymal platforms, while neural precursors are advancing for central nervous system indications. Embryonic stem cells are carving niches where pluripotency is essential, complemented by perinatal populations such as amniotic fluid and umbilical cord cells that combine ethical acceptability with robust differentiation capacity.

On the technological front, biomaterial-enhanced constructs and scaffold systems are optimizing cell delivery and retention. Gene-edited technologies are refining therapeutic specificity by eliminating immunogenic markers and correcting pathogenic variants. Ex vivo expansion solutions are seamlessly integrated with automated bioreactors to deliver consistent cell quality at scale. In parallel, the choice of administration route-ranging from intra-articular injections for musculoskeletal applications to intravenous infusions for systemic disorders-is being tailored to both clinical objectives and patient comfort.

Applications in drug discovery are utilizing stem cell-derived models to predict toxicity and efficacy, while regenerative medicine platforms target tissue restoration across cardiovascular, neurological, and musculoskeletal domains. Tissue engineering collaborations are producing hybrid constructs for organ repair. Across these domains, academic and research institutes fuel basic science discoveries, biopharmaceutical companies shepherd translational programs, hospitals and clinics drive clinical trial enrollment and real-world evidence collection, and specialized stem cell banks underpin both supply reliability and quality assurance.

Mapping Key Regional Dynamics, Growth Opportunities, and Emerging Trends Across the Americas, Europe Middle East Africa, and Asia-Pacific Stem Cell Therapy Markets

Regional dynamics play a decisive role in shaping the trajectory of stem cell therapy development and commercialization. In the Americas, the United States leads with a robust funding environment, established clinical trial infrastructure, and a regulatory framework that balances patient safety with accelerated pathways. Canada is bolstering its position through strategic funding of translational research hubs, while Latin American countries are beginning to attract international partnerships by leveraging cost-effective clinical networks and supportive government incentives.

Within Europe, Middle East, and Africa, Europe's landscape is characterized by harmonized regulatory guidelines and a vibrant community of centers of excellence. Western European nations are driving first-in-human studies, while emerging markets in the Middle East and North Africa are investing in biomanufacturing capacity and public-private innovation clusters. Collaborative frameworks between the European Medicines Agency and regional authorities are laying the foundation for unified compassionate use programs and standardized quality controls.

In the Asia-Pacific arena, nations such as Japan and South Korea have established favorable cell therapy roadmaps, including conditional approvals and reimbursement models that mitigate development risk. China's expansive clinical trial footprint and growing network of contract development and manufacturing organizations present both opportunities and competitive pressures. India, Australia, and Southeast Asian nations are accelerating research through government grants and cross-border research partnerships, creating a diverse ecosystem that spans early-stage discovery to late-stage commercialization.

Examining Strategic Positioning and Innovation Roadmaps of Leading Global Developers in the Evolving Stem Cell Therapy Industry Landscape

The competitive landscape of stem cell therapy is defined by organizations that excel in scientific innovation, regulatory navigation, and strategic partnerships. Leading companies have demonstrated the capacity to advance early-stage research into pivotal trials by integrating proprietary technologies with robust manufacturing platforms. Some innovators are focusing on gene-edited allogeneic cell lines to address rare genetic disorders, while others are optimizing mesenchymal stem cell constructs for inflammatory conditions and tissue repair.

Strategic alliances between biotech firms and large pharmaceutical companies are accelerating late-stage clinical development, leveraging established distribution channels and deep reimbursement expertise. Contract development and manufacturing organizations are stepping into the spotlight by offering end-to-end solutions, from cell banking through fill-and-finish operations, thereby de-risking capital expenditure for small to mid-sized developers.

In parallel, a number of academic spin-off enterprises are carving out niches by translating novel differentiation protocols or biomaterial formulations into early-phase trials. Venture capital and strategic corporate investors continue to back these high-potential ventures, focusing on pipelines that span oncology to neurological diseases. Collectively, these stakeholders are reshaping the sector by aligning scientific ambition with commercial pragmatism, setting new benchmarks for efficacy, safety, and scalability.

Implementable Strategies and Best Practices Designed to Accelerate Innovation, Optimize Operational Frameworks, and Enhance Collaboration in Stem Cell Therapy

Industry leaders should prioritize investment in modular manufacturing systems that allow rapid scale-up and flexible adaptation to multiple cell types and therapeutic targets. By adopting single-use bioreactors and closed-system processing, organizations can minimize cross-contamination risk and accelerate technology transfer across facilities. Concurrently, forging strategic alliances with reagent suppliers and specialized equipment vendors will secure preferential access to critical inputs and foster co-development initiatives.

To navigate evolving regulatory landscapes, companies must implement proactive engagement strategies with health authorities, submitting data packages that emphasize process validation and real-world evidence. Leveraging adaptive trial designs can shorten timelines while preserving rigorous safety and efficacy standards. Building global trial networks and harmonizing clinical protocols will also reduce duplicate efforts and streamline patient recruitment.

Furthermore, embracing digital health solutions-such as remote monitoring, electronic patient-reported outcomes, and blockchain-enabled supply chain tracking-will enhance transparency, patient adherence, and quality control. Finally, cultivating cross-disciplinary talent through targeted training programs and academic collaborations will ensure the workforce remains adept at integrating emerging science with commercial imperatives, laying the groundwork for sustainable growth.

Rigorous Methodological Approach Combining Qualitative Interviews, Quantitative Data Analysis, and Expert Validation to Ensure Robust Stem Cell Therapy Insights

This research is founded upon a mixed-methods approach that integrates qualitative and quantitative data to produce a holistic view of the stem cell therapy sector. Primary research was conducted through in-depth interviews with executives from leading biopharmaceutical firms, regulatory agency representatives, academic investigators, and contract manufacturing experts. These discussions provided nuanced understanding of development challenges, investment priorities, and adoption barriers.

Secondary research encompassed a thorough review of peer-reviewed publications, patent filings, government policy documents, and public company disclosures. Data points were triangulated to verify consistency and identify divergent trends across sources. Proprietary databases tracking clinical trial activities, technology licensing agreements, and capital investment flows were also leveraged to ensure comprehensive coverage.

All quantitative inputs underwent rigorous validation through cross-referencing with expert feedback. Key assumptions were stress-tested under multiple scenarios to assess impact on operational and regulatory variables. The resulting framework ensures that insights are both robust and actionable, offering stakeholders a reliable foundation for strategic decision-making in this rapidly evolving domain.

Synthesizing Critical Discoveries and Identifying Future Pathways to Propel the Next Generation of Therapeutic Breakthroughs in Stem Cell Applications Worldwide

The synthesis of technological advances, policy shifts, and market dynamics underscores a pivotal moment for the maturation of stem cell therapies. Breakthroughs in gene regulation and cell manufacturing are converging to overcome historical bottlenecks in scale and consistency. At the same time, evolving regulatory policies and strategic collaborations are de-risking development pathways and fostering an environment conducive to innovation.

Segmentation insights reveal that no single approach will dominate; rather, a diversified portfolio encompassing allogeneic and autologous products, multiple cell sources, and varied delivery platforms will characterize the next phase of growth. Regional analyses highlight that global market penetration will depend on tailoring strategies to local regulatory, reimbursement, and infrastructure conditions.

Ultimately, success in this arena will hinge on aligning scientific rigor with commercial agility, forging partnerships across the ecosystem, and maintaining an unwavering focus on patient-centered outcomes. By synthesizing these critical discoveries and identifying future pathways, stakeholders are better positioned to usher in the next generation of therapeutic breakthroughs and deliver transformative care to patients around the world.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Stem Cell Therapy Market, by Therapy Type

  • 8.1. Allogeneic Therapy
  • 8.2. Autologous Therapy

9. Stem Cell Therapy Market, by Cell Source

  • 9.1. Adult Stem Cells
    • 9.1.1. Hematopoietic Stem Cells
    • 9.1.2. Mesenchymal Stem Cells
    • 9.1.3. Neural Stem Cells
  • 9.2. Embryonic Stem Cells
  • 9.3. Induced Pluripotent Stem Cells
  • 9.4. Perinatal Stem Cells
    • 9.4.1. Amniotic Fluid Stem Cells
    • 9.4.2. Umbilical Cord Stem Cells

10. Stem Cell Therapy Market, by Technology

  • 10.1. Biomaterial Based Therapy
  • 10.2. Ex Vivo Expansion
  • 10.3. Gene Edited Technologies
  • 10.4. Scaffold Based Therapy

11. Stem Cell Therapy Market, by Mode of Administration

  • 11.1. Intra-articular
  • 11.2. Intramuscular
  • 11.3. Intravenous

12. Stem Cell Therapy Market, by Application

  • 12.1. Drug Discovery & Development
  • 12.2. Regenerative Medicine
  • 12.3. Tissue Engineering

13. Stem Cell Therapy Market, by Therapeutic Areas

  • 13.1. Cardiovascular Diseases
  • 13.2. Hematology
  • 13.3. Musculoskeletal Disorders
  • 13.4. Neurological Disorders
  • 13.5. Oncology

14. Stem Cell Therapy Market, by End User

  • 14.1. Academic & Research Institutes
  • 14.2. Biopharmaceutical Companies
  • 14.3. Hospitals & Clinics
  • 14.4. Stem Cell Banks

15. Stem Cell Therapy Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Stem Cell Therapy Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Stem Cell Therapy Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Stem Cell Therapy Market

19. China Stem Cell Therapy Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Anterogen Co., Ltd.
  • 20.6. Astellas Pharma Inc.
  • 20.7. Beike Biotechnology Co., Ltd.
  • 20.8. BrainStorm Cell Therapeutics Inc.
  • 20.9. Bristol-Myers Squibb Company
  • 20.10. CellProthera SAS
  • 20.11. Fate Therapeutics, Inc.
  • 20.12. Gamida Cell Ltd.
  • 20.13. Garuda Therapeutics
  • 20.14. Holostem Terapie Avanzate S.r.l.
  • 20.15. Jasper Therapeutics, Inc.
  • 20.16. JCR Pharmaceuticals Co., Ltd.
  • 20.17. Juvena Therapeutics Inc.
  • 20.18. Kangstem Biotech Co., Ltd.
  • 20.19. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 20.20. Lonza Group AG
  • 20.21. Medeze Group
  • 20.22. Merck KGaA
  • 20.23. Mesoblast Ltd.
  • 20.24. Novo Nordisk A/S
  • 20.25. Plasticell
  • 20.26. ReNeuron Group PLC
  • 20.27. SQZ Biotechnologies Company by Stemcell Technologies
  • 20.28. Takara Bio Inc.
  • 20.29. Thermo Fisher Scientific Inc.
  • 20.30. U.S. Stem Cell Inc
  • 20.31. Umoja Biopharma
  • 20.32. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOMATERIAL BASED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOMATERIAL BASED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOMATERIAL BASED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EX VIVO EXPANSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EX VIVO EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EX VIVO EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GENE EDITED TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GENE EDITED TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GENE EDITED TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STEM CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STEM CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STEM CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRA-ARTICULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRA-ARTICULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL STEM CELL THERAPY MARKET SIZE, BY STEM CELL BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL STEM CELL THERAPY MARKET SIZE, BY STEM CELL BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL STEM CELL THERAPY MARKET SIZE, BY STEM CELL BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS STEM CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. G7 STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. G7 STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)